Corbus Pharmaceuticals (NASDAQ:CRBP - Get Free Report)'s stock had its "buy" rating reiterated by equities researchers at HC Wainwright in a report released on Wednesday,Benzinga reports. They presently have a $50.00 price target on the biopharmaceutical company's stock, down from their prior price target of $75.00.
Other equities analysts have also issued reports about the company. Jefferies Financial Group dropped their target price on Corbus Pharmaceuticals from $70.00 to $53.00 and set a "buy" rating for the company in a research note on Tuesday. StockNews.com raised shares of Corbus Pharmaceuticals to a "sell" rating in a research note on Thursday, March 6th. Piper Sandler started coverage on shares of Corbus Pharmaceuticals in a research note on Monday, December 2nd. They set an "overweight" rating and a $35.00 price objective for the company. Finally, William Blair initiated coverage on Corbus Pharmaceuticals in a research report on Friday, February 28th. They set an "outperform" rating for the company. One investment analyst has rated the stock with a sell rating, nine have assigned a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $59.13.
Check Out Our Latest Report on CRBP
Corbus Pharmaceuticals Price Performance
Shares of NASDAQ CRBP opened at $6.88 on Wednesday. The company has a market cap of $83.79 million, a PE ratio of -1.47 and a beta of 2.63. The stock has a fifty day moving average price of $9.77 and a 200 day moving average price of $19.53. Corbus Pharmaceuticals has a 1-year low of $6.54 and a 1-year high of $61.90.
Corbus Pharmaceuticals (NASDAQ:CRBP - Get Free Report) last issued its earnings results on Tuesday, March 11th. The biopharmaceutical company reported ($0.78) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.02) by $0.24. Analysts anticipate that Corbus Pharmaceuticals will post -4.23 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Large investors have recently added to or reduced their stakes in the stock. Vestcor Inc acquired a new stake in shares of Corbus Pharmaceuticals in the 3rd quarter valued at about $64,000. JPMorgan Chase & Co. lifted its holdings in Corbus Pharmaceuticals by 27.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 5,507 shares of the biopharmaceutical company's stock worth $114,000 after buying an additional 1,172 shares during the last quarter. MetLife Investment Management LLC acquired a new position in shares of Corbus Pharmaceuticals in the 3rd quarter worth approximately $123,000. Wells Fargo & Company MN increased its holdings in shares of Corbus Pharmaceuticals by 51.7% in the 4th quarter. Wells Fargo & Company MN now owns 6,444 shares of the biopharmaceutical company's stock valued at $76,000 after acquiring an additional 2,195 shares during the last quarter. Finally, Avanza Fonder AB acquired a new stake in shares of Corbus Pharmaceuticals during the 4th quarter valued at approximately $84,000. 64.64% of the stock is currently owned by institutional investors.
About Corbus Pharmaceuticals
(
Get Free Report)
Corbus Pharmaceuticals Holdings, Inc, a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Corbus Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Corbus Pharmaceuticals wasn't on the list.
While Corbus Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
